

Table 4 Ratios of measured values of variables

	Group	T0	T1	T2	T3	T5	T7	T10
QT/baseline	Sugammadex	1.00 ± 0.02	0.99 ± 0.02	0.99 ± 0.03	0.99 ± 0.04	0.98 ± 0.04	0.98 ± 0.03	0.98 ± 0.05
	Neostigmine	1.00 ± 0.01	0.95 ± 0.03*†	0.96 ± 0.04*†	0.97 ± 0.03*†	0.99 ± 0.03	1.01 ± 0.03	1.00 ± 0.05
QTcB/baseline	Sugammadex	1.00 ± 0.01	0.99 ± 0.02	1.00 ± 0.02	1.00 ± 0.02	1.00 ± 0.01	1.00 ± 0.02	1.00 ± 0.02
	Neostigmine	1.00 ± 0.02	1.03 ± 0.04*†	1.00 ± 0.02	0.99 ± 0.02	0.98 ± 0.02	0.99 ± 0.04	0.98 ± 0.03
QTcF/baseline	Sugammadex	1.00 ± 0.02	1.00 ± 0.02	1.00 ± 0.01	1.00 ± 0.01	0.99 ± 0.02	1.00 ± 0.02	0.99 ± 0.02
	Neostigmine	1.00 ± 0.02	1.00 ± 0.02	0.98 ± 0.02	0.99 ± 0.05	0.99 ± 0.02	0.99 ± 0.03	0.99 ± 0.02
QTD/baseline	Sugammadex	1.04 ± 0.29	1.04 ± 0.21	1.04 ± 0.34	1.06 ± 0.38	1.16 ± 0.45	1.05 ± 0.34	1.03 ± 0.29
	Neostigmine	1.04 ± 0.23	1.11 ± 0.42	1.10 ± 0.30	1.15 ± 0.49	1.09 ± 0.58	1.18 ± 0.49	1.19 ± 0.42
QTcBD/baseline	Sugammadex	1.08 ± 0.47	0.97 ± 0.13	0.93 ± 0.31	0.94 ± 0.25	1.01 ± 0.20	0.97 ± 0.28	0.93 ± 0.20
	Neostigmine	1.13 ± 0.2	1.31 ± 0.39*†	1.32 ± 0.33*†	1.34 ± 0.45*†	1.21 ± 0.40	1.23 ± 0.45	1.07 ± 0.28
QTcFD/baseline	Sugammadex	0.99 ± 0.28	1.00 ± 0.37	1.04 ± 0.30	1.03 ± 0.36	1.02 ± 0.36	1.10 ± 0.34	1.07 ± 0.31
	Neostigmine	1.07 ± 0.23	1.22 ± 0.35	1.22 ± 0.27	1.38 ± 0.48*†	1.15 ± 0.32	1.19 ± 0.40	1.04 ± 0.29

Data are presented as mean ± standard deviation. *p < 0.05 versus sugammadex group. †p < 0.05 versus baseline ratio. T0: reversal of neuromuscular blockade, T1–T10: 1–10 min after reversal, RR: RR interval, QT: QT interval, QTcB: QT corrected using Bazzett's formula, QTcF: QT corrected using Fredericia's formula, QTD: QT dispersion, QTcBD: QT dispersion corrected using Bazzett's formula, QTcFD: QT dispersion corrected using Fredericia's formula